Fig. 5From: Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitorsFrequency of p.T790M acquisition in dependence on primary driver mutation. Frequency of total p.T790M acquisition in patients under reversible (a) and irreversible (b) EGFR TKI therapy for > 6 months, respectively. Frequency of p.T790M acquisition in EGFR Exon 19 mutated patients differs significantly in reversible and irreversible EGFR TKI treated patients determined by Qui Square test (p = 0.005)Back to article page